Amneal stock: buy or sell?

AMRX stock price: $5.10 -4.67% At close on January 17th, 2020

Updated on:
January 17th, 2020


Shares of Amneal plunged a hair-raising -4.67% and closed at $5.10. On Tuesday AMRX climbed an amazing 10.36%.

Should I buy Amneal stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

None of our preferred buy setups matches with Amneal stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean AMRX will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Amneal Pharmaceuticals stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we gathered 15 ratings published for AMRX stock in the last month.

The general sentiment of these ratings is bullish for AMRX stock, with 8 positive ratings.
Is AMRX a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-6SunTrust Banksn/aBuy
2019-8-6BMO Capital Marketsn/aMarket Perform
2019-7-8Piper Jaffray CompaniesNeutralOverweight
2019-7-22Svb LeerinkMarket PerformOutperform
2019-7-22Leerink Swannn/aOutperform
2019-7-11SunTrust Banksn/aBuy
2019-7-11Royal Bank of CanadaOutperformSector Perform
2019-7-10Raymond JamesStrong-BuyOutperform
2019-6-12Cantor Fitzgeraldn/aOverweight
2019-6-11Barclaysn/aEqual Weight
2019-5-21Raymond JamesMarket PerformStrong-Buy
2019-3-8Svb LeerinkOutperformMarket Perform
2019-3-8Leerink Swannn/aMarket Perform
2019-3-19SunTrust Banksn/aBuy

Amneal stock analysis

Daily outlook

Shares of Amneal Pharmaceuticals ended yesterday at $5.10 and plunged a hair-raising -4.67%.

Amneal Pharmaceuticals ended yesterday at $5.10 and plunged a hair-raising -4.67%. Since SMA50d and SMA100d crossed up on December, AMRX price climbed $1.06 per share (26.24%). Since November when AMRX stock price broke up the SMA100d line, it gained $2.06 (67.76%).

AMRX stock chart (daily)

Weekly outlook

Amneal Pharmaceuticals shares skyrocketed 13.08% this week, ending at $5.10. Late December 2019 AMRX plummed a frightening -7.32% in just one week.

Amneal stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since mid November 2019 when AMRX stock price broke up the SMA20w line, it gained $2.35 (85.45%).

AMRX stock chart (weekly)

Amneal stock price history

Amneal IPO was on May 7th, 2018 at $17.00 per share1. Since then, AMRX stock lost a -70.00%, with a yearly average of -70.00%.

1: Adjusted price after possible price splits or reverse-splits.

Amneal stock historical price chart

AMRX stock reached 52-week highs on March at $14.79, and all-time highs 2018-08-22 with a price of 24.48.

Amneal stock price target is $8.30

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 11 price targets for Amneal stock:
AMRX stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-6SunTrust BanksReiteratesn/a$5.00-
2019-8-6BMO Capital MarketsLowers Target$6.00$5.00-16.7%
2019-7-8Piper Jaffray CompaniesUpgradesn/a$11.00-
2019-7-22Svb LeerinkUpgrades$11.00$5.00-54.5%
2019-7-11SunTrust BanksReiterates$16.00$9.00-43.8%
2019-7-11Royal Bank of CanadaDowngrades$11.00$6.00-45.5%
2019-6-12Cantor FitzgeraldReiterates$35.00$14.00-60%
2019-5-21Raymond JamesUpgradesn/a$13.00-
2019-3-8Svb LeerinkDowngrades$16.00$12.00-25%
(in average)$15.80$8.30-47.0%
The price target for Amneal Pharmaceuticals stock is $8.30, moving in a range between $14.00 and $2.50. In average, analysts' outlook on AMRX price target is negative, reducing the target by a -47.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After posting its last earnings report on May, Amneal Pharmaceuticals . As soon as we get its posted EPS from the earnings report, we will update this review.
AMRX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Amneal annual revenues skyrocketed a dazzling 60.89% to $1,662.99 million dollars from $1,033.65 marked in 2017. In contrary, its earnings margin (compared to revenues) decreased to -1.26%, that is $-20.92 million.

Amneal Pharmaceuticals fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Amneal Pharmaceuticals TTM sales up to were $1,387.80 and income $-20.92 million dollars. When comparing this TTM figures with the last reported annuality, we can esteem Amneal Pharmaceuticals business evolution since December 2018: Annual turnover up to , compared to lastest yearly report, plummed a spooky -16.55%. Regarding profit margin, Amneal Pharmaceuticals stayed stable -0.25% to -1.26%

AMRX annual Sales and Income evolution
2013$512 M-$101 M19.8%-
2014$596 M16.53%$57 M9.6%-43.36%
2015$860 M44.36%$39 M4.5%-32.00%
2016$1,018 M18.33%$0.00 M0.0%-100.00%
2017$1,034 M1.52%$0.00 M0.0%0.00%
2018$1,663 M60.89%$-20.92 M-1.3%0.00%
TTM $1,388 M-16.55%$-20.92 M-1.5%0.00%

Quarterly financial results

Amneal Pharmaceuticals reported M in revenues for 2019-Q1, a -100.00% less compared to previous quarter. Reported quarter income marked M with a profit margin of . Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was -1.76%. When comparing sales to same quarter last year, Amneal sales marked a tight movement and remained steady a nan%.
AMRX quarterly Sales and Income evolution
2017-Q1$184 M-$-98.43 M-53.4%-
2017-Q2$260 M40.93%$37.45 M14.4%-138.04%
2017-Q3$255 M-1.98%$0.00 M0.0%-100.00%
2017-Q4$183 M-28.20%$-301.07 M-164.6%0.00%
2018-Q2$414 M126.22%$-19.10 M-4.6%-93.65%
2018-Q3$476 M15.15%$6.95 M1.5%-136.39%
2018-Q4$498 M4.42%$-8.77 M-1.8%-226.12%

Amneal ownership

When you are planning to invest in shares of a company, it's always worth to check its ownership structure.

Amneal shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 13.06% of all shares.

In case of Amneal stock, 76.70% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AMRX stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related stocks:

Market cap$683.9 M
Total shares134.1 M
Float shares82.3 M
  - Institutional holdings (%)76.7%
  - Insider holdings (%)13.1%
Shares in short selling0.0%

Amneal summary

Friday, January 17th, 2020
Day range$5.02 - $5.44
Previous close$5.35
Session gain-4.67%
Average true range$0.33
50d mov avg$4.01
100d mov avg$3.53
200d mov avg$5.53
Daily pattern
Weekly pattern lt06a

Amneal performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Amneal Pharmaceuticals, the comparison is made against .
AMRXAmneal Pharmaceut...70.57%50.00%-58.94%

Amneal competitors

Unfortunately, we could not find any public company that could be defined as Amneal Pharmaceuticals competitor. This doesn't mean Amneal Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.